Xiaoqin Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaoqin Wang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Liwen Zhang
Department of Obstetrics and Gynecology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, 200240, China; Center of Community-Based Health Research, Fudan University, Shanghai, 200240, China
4 shared publications Ningning Hu
Department of Obstetrics and Gynecology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, 200240, China; Center of Community-Based Health Research, Fudan University, Shanghai, 200240, China
4 shared publicationsRujun Chen
Department of Obstetrics and Gynecology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, 200240, China; Center of Community-Based Health Research, Fudan University, Shanghai, 200240, China
4 shared publicationsLingling Zhang
Department of Obstetrics and Gynecology, Shanghai Fifth People’s Hospital, Fudan University
2 shared publicationsLiwen Zhang
2 shared publications- Rujun Chen
Department of Obstetrics and Gynecology, Shanghai Fifth People’s Hospital, Fudan University, China
2 shared publications
Latest Publications
- Open Access
- 10 September 2026
- Published by Elsevier in Tissue and Cell
- Vol. 104 (Pt 2) , 103950
Ghrelin attenuates hypoxia-induced mitochondrial oxidative stress damage in HTR-8/SVneo trophoblasts
- 10 September 2026
- Published by Elsevier in Tissue and Cell
- Vol. 104 (Pt 2) , 103950
Open AccessGhrelin attenuates hypoxia-induced mitochondrial oxidative stress damage in HTR-8/SVneo trophoblasts
- Open Access
- 29 May 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (6) , 809
The Ghrelin/GHSR-1a Axis Attenuates Preeclampsia-like Features with Decidual Macrophage Reprogramming and Improved Placental Remodeling
Preeclampsia (PE) is a severe pregnancy-specific hypertensive disorder characterized by immune microenvironment dysregulation at the maternal–fetal interface, with decidual macrophage phenotypic imbalance being a key pathological feature. The Ghrelin/growth hormone secretagogue receptor-1a (GHSR-1a) axis exerts immunomodulatory and anti-inflammatory effects, but its role in regulating decidual macrophage infiltration and phenotypic marker expression in PE remains unclear. In this study, we first detected the expression of the Ghrelin/GHSR-1a axis in decidual tissues from 10 healthy pregnant women and 12 PE patients via immunohistochemistry (IHC). We then established a lipopolysaccharide (LPS)-induced PE-like rat model to investigate the axis’s functional role and underlying mechanisms. Intriguingly, clinical analysis revealed a severity-dependent compensatory escalation of the Ghrelin/GHSR-1a axis in PE decidual tissues, potentially representing an endogenous antagonistic response to pregnancy-associated pathological stress. In the animal model, exogenous Ghrelin supplementation reversed LPS-induced PE-like phenotypes, including hypertension, proteinuria, fetal growth restriction (FGR), and placental dysfunction, and alleviated pathological damage to the maternal liver, kidney, and placenta. Mechanistically, Ghrelin modulated decidual macrophage phenotypic marker expression by downregulating the M1 marker CD86 and upregulating the M2 marker CD163 and promoted trophoblast invasion and spiral artery remodeling by restoring laminin, α-cytokeratin 7 (α-CK7), and α-smooth muscle actin (α-SMA) expression in placental tissue. All protective effects of Ghrelin were abrogated by co-administration of D-lys-3-GHRP-6, a specific GHSR-1a antagonist, confirming the dependence on the Ghrelin/GHSR-1a axis. Collectively, our findings suggest that the Ghrelin/GHSR-1a axis is compensatorily upregulated in PE and may exert a protective role by regulating decidual macrophage phenotypic marker expression and improving placental function, providing preliminary evidence that this axis merits further investigation as a potential research target for PE.
- 29 May 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (6) , 809
Open AccessThe Ghrelin/GHSR-1a Axis Attenuates Preeclampsia-like Features with Decidual Macrophage Reprogramming and Improved Placental Remodeling
Preeclampsia (PE) is a severe pregnancy-specific hypertensive disorder characterized by immune microenvironment dysregulation at the maternal–fetal interface, with decidual macrophage phenotypic imbalance being a key pathological feature. The Ghrelin/growth hormone secretagogue receptor-1a (GHSR-1a) axis exerts immunomodulatory and anti-inflammatory effects, but its role in regulating decidual macrophage infiltration and phenotypic marker expression in PE remains unclear. In this study, we first detected the expression of the Ghrelin/GHSR-1a axis in decidual tissues from 10 healthy pregnant women and 12 PE patients via immunohistochemistry (IHC). We then established a lipopolysaccharide (LPS)-induced PE-like rat model to investigate the axis’s functional role and underlying mechanisms. Intriguingly, clinical analysis revealed a severity-dependent compensatory escalation of the Ghrelin/GHSR-1a axis in PE decidual tissues, potentially representing an endogenous antagonistic response to pregnancy-associated pathological stress. In the animal model, exogenous Ghrelin supplementation reversed LPS-induced PE-like phenotypes, including hypertension, proteinuria, fetal growth restriction (FGR), and placental dysfunction, and alleviated pathological damage to the maternal liver, kidney, and placenta. Mechanistically, Ghrelin modulated decidual macrophage phenotypic marker expression by downregulating the M1 marker CD86 and upregulating the M2 marker CD163 and promoted trophoblast invasion and spiral artery remodeling by restoring laminin, α-cytokeratin 7 (α-CK7), and α-smooth muscle actin (α-SMA) expression in placental tissue. All protective effects of Ghrelin were abrogated by co-administration of D-lys-3-GHRP-6, a specific GHSR-1a antagonist, confirming the dependence on the Ghrelin/GHSR-1a axis. Collectively, our findings suggest that the Ghrelin/GHSR-1a axis is compensatorily upregulated in PE and may exert a protective role by regulating decidual macrophage phenotypic marker expression and improving placental function, providing preliminary evidence that this axis merits further investigation as a potential research target for PE.
- Open Access
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1819374
Resveratrol ameliorates intrahepatic cholestasis of pregnancy by modulating the gut-liver axis and FXR-mediated bile acid homeostasis
Objective: Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder with limited treatment options. This study investigated the therapeutic potential of resveratrol (RES) and its underlying mechanisms, focusing on the gut-liver axis and bile acid metabolism in an estrogen-induced ICP rat model. Methods: Pregnant rats were randomized into Sham, ICP (induced by 17β-estradiol), and ICP+RES (15, 30, 60 mg/kg) groups. Systemic and hepatic inflammation, liver function, histopathology, and intestinal barrier integrity were assessed. Hepatic bile acid profiles were analyzed by UHPLC-MS/MS, and gut microbiota was evaluated by 16S rRNA sequencing. The role of gut microbiota was further examined via fecal microbiota transplantation (FMT) in pseudogerm-free rats. Key proteins in the FXR signaling pathway were analyzed by Western blotting. Results: RES treatment dose-dependently alleviated ICP manifestations, including reducing serum levels of total bile acids, total bilirubin, and liver enzymes (AST, ALT, ALP), while mitigating systemic and hepatic inflammation. It also restored intestinal barrier integrity and corrected gut microbiota dysbiosis. FMT from RES-treated donors recapitulated these therapeutic effects in recipient ICP rats. Furthermore, RES reversed the hepatic bile acid imbalance by reducing primary bile acids and increasing beneficial secondary bile acids. Mechanistically, RES upregulated the expression of FXR and its downstream targets, including SHP, BSEP, UGT2B4, and CYP1A1. Conclusion: RES effectively ameliorated ICP through multi-faceted mechanisms involving the attenuation of inflammation, restoration of gut microbiota and intestinal barrier, and correction of bile acid homeostasis via activation of the FXR signaling pathway. Our findings highlight RES as a promising multi-mechanistic therapeutic candidate for ICP.
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1819374
Open AccessResveratrol ameliorates intrahepatic cholestasis of pregnancy by modulating the gut-liver axis and FXR-mediated bile acid homeostasis
Objective: Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder with limited treatment options. This study investigated the therapeutic potential of resveratrol (RES) and its underlying mechanisms, focusing on the gut-liver axis and bile acid metabolism in an estrogen-induced ICP rat model. Methods: Pregnant rats were randomized into Sham, ICP (induced by 17β-estradiol), and ICP+RES (15, 30, 60 mg/kg) groups. Systemic and hepatic inflammation, liver function, histopathology, and intestinal barrier integrity were assessed. Hepatic bile acid profiles were analyzed by UHPLC-MS/MS, and gut microbiota was evaluated by 16S rRNA sequencing. The role of gut microbiota was further examined via fecal microbiota transplantation (FMT) in pseudogerm-free rats. Key proteins in the FXR signaling pathway were analyzed by Western blotting. Results: RES treatment dose-dependently alleviated ICP manifestations, including reducing serum levels of total bile acids, total bilirubin, and liver enzymes (AST, ALT, ALP), while mitigating systemic and hepatic inflammation. It also restored intestinal barrier integrity and corrected gut microbiota dysbiosis. FMT from RES-treated donors recapitulated these therapeutic effects in recipient ICP rats. Furthermore, RES reversed the hepatic bile acid imbalance by reducing primary bile acids and increasing beneficial secondary bile acids. Mechanistically, RES upregulated the expression of FXR and its downstream targets, including SHP, BSEP, UGT2B4, and CYP1A1. Conclusion: RES effectively ameliorated ICP through multi-faceted mechanisms involving the attenuation of inflammation, restoration of gut microbiota and intestinal barrier, and correction of bile acid homeostasis via activation of the FXR signaling pathway. Our findings highlight RES as a promising multi-mechanistic therapeutic candidate for ICP.
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (2) , 123
A panel of machine learning approaches for diagnostic model development and validation in ovarian cancer
Background: Ovarian cancer is a lethal gynecological malignancy, with ~70% of patients diagnosed at advanced stages (5-year survival Methods: We analyzed five Gene Expression Omnibus (GEO) datasets, with GSE26712, GSE29156, and GSE40595 assigned as the training cohort, and GSE66957 and GSE119054 as independent validation cohorts. Following batch effect correction, 113 ML algorithms were systematically compared. The optimal model was further validated, and its core genes [model gene (Mgenes)] were subjected to functional enrichment and immune cell correlation analyses. Results: The least absolute shrinkage and selection operator (Lasso) + NaiveBayes model demonstrated the strongest diagnostic performance, with area under the receiver operating characteristic curve (AUC) values of 0.991 in the training set, 0.889 in GSE119054, and 0.936 in GSE66957, and achieved 100% recall in both validation cohorts. Twelve Mgenes were identified, among which CP exhibited the highest diagnostic value (AUC =0.966). Functional enrichment revealed that Mgenes were predominantly involved in cell cycle regulation and DNA replication pathways, and correlation analyses confirmed their associations with key immune subsets (e.g., MAOB with regulatory T cells, STAR with CD8+ T cells). Conclusions: The Lasso + NaiveBayes model enables robust ovarian cancer diagnosis, with high recall prioritizing the identification of all potential cases. The identified Mgenes act as both high-performance diagnostic biomarkers and functional mediators of tumorigenesis, laying a foundation for early detection strategies and mechanistic research into ovarian cancer.
- 1 February 2026
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 15 (2) , 123
Open AccessA panel of machine learning approaches for diagnostic model development and validation in ovarian cancer
Background: Ovarian cancer is a lethal gynecological malignancy, with ~70% of patients diagnosed at advanced stages (5-year survival Methods: We analyzed five Gene Expression Omnibus (GEO) datasets, with GSE26712, GSE29156, and GSE40595 assigned as the training cohort, and GSE66957 and GSE119054 as independent validation cohorts. Following batch effect correction, 113 ML algorithms were systematically compared. The optimal model was further validated, and its core genes [model gene (Mgenes)] were subjected to functional enrichment and immune cell correlation analyses. Results: The least absolute shrinkage and selection operator (Lasso) + NaiveBayes model demonstrated the strongest diagnostic performance, with area under the receiver operating characteristic curve (AUC) values of 0.991 in the training set, 0.889 in GSE119054, and 0.936 in GSE66957, and achieved 100% recall in both validation cohorts. Twelve Mgenes were identified, among which CP exhibited the highest diagnostic value (AUC =0.966). Functional enrichment revealed that Mgenes were predominantly involved in cell cycle regulation and DNA replication pathways, and correlation analyses confirmed their associations with key immune subsets (e.g., MAOB with regulatory T cells, STAR with CD8+ T cells). Conclusions: The Lasso + NaiveBayes model enables robust ovarian cancer diagnosis, with high recall prioritizing the identification of all potential cases. The identified Mgenes act as both high-performance diagnostic biomarkers and functional mediators of tumorigenesis, laying a foundation for early detection strategies and mechanistic research into ovarian cancer.
- Open Access
- 29 January 2025
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 47 (3) , 102772
sFlt-1, Coagulation Function, and Platelets as Predictors of Preeclampsia
- 29 January 2025
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 47 (3) , 102772
Open AccesssFlt-1, Coagulation Function, and Platelets as Predictors of Preeclampsia
- Open Access
- 7 April 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 972, 176569
Ghrelin alleviates placental dysfunction by down-regulating NF-κB phosphorylation in LPS-induced rat model of preeclampsia
- 7 April 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 972, 176569
Open AccessGhrelin alleviates placental dysfunction by down-regulating NF-κB phosphorylation in LPS-induced rat model of preeclampsia